Your Article Summary
See Latest ArticlesReversal of refractory septic shock with drotrecogin alpha (activated)
Intensive Care Medicine, 07/02/09
Vieillard-Baron A et al. - The objective of this study was to investigate whether early administration of drotrecogin alpha (activated) (DrotAA) to this selected subgroup of septic patients at extremely high risk of death would significantly improve prognosis. DrotAA therapy was associated with unexpectedly high 28-day survival in patients with "refractory" septic shock.
Related Articles
Standardized order sets for the treatment of severe sepsis and septic shock
Expert Review of Anti-infective Therapy, 11/12/09
Relevance Score: 69%
An explorative study on quality of life and psychological and cognitive function in pediatric survivors of septic shock
Pediatric Critical Care, 11/10/09
Relevance Score: 69%
Corticosteroids for severe sepsis and septic shock
Intensivmedizin und Notfallmedizin, 11/06/09
Relevance Score: 69%
Is pituitary failure the real therapeutic target in septic shock
Medical Hypotheses, 11/04/09
Relevance Score: 69%
Beta-2-Adrenergic Receptor Gene Polymorphism is Associated with Mortality in Septic Shock
American Journal of Respiratory and Critical Care Medicine, 10/27/09
Relevance Score: 68%
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Comparative Effectiveness of 5 Smoking Cessation Pharmacotherapies in Primary Care Clinics
Archives of Internal Medicine, 12/14/09
Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data
The Lancet, 12/14/09